Assisted Reproductive Technology Market Projected to Reach USD 69.5 Billion by 2034 – SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - Artificial intelligence and machine learning are moving from pilot projects to routine use inside fertility labs, reshaping how embryos are selected and how treatment plans are built around individual patients. That technology shift is reinforcing an already fast-growing market: the assisted reproductive technology (ART) market was valued at USD 32.0 billion in 2025 and is projected to reach USD 69.5 billion by 2034, growing at a CAGR of 9.00% between 2026 and 2034, according to a new report from Strategic Revenue Insights Inc. The findings are led by lead analyst Lukas Schmidt, and the report is built on primary interviews with fertility clinics, hospitals and surgical centers, cryobanks, and research institutes, combined with secondary research spanning Asia Pacific, North America, Latin America, Europe, and Middle East & Africa.

Key Takeaways

• The ART market is valued at USD 32.0 billion in 2025 and is forecast to reach USD 69.5 billion by 2034, at a CAGR of 9.00%.
• In Vitro Fertilization is the largest procedure-type segment, while Preimplantation Genetic Testing is the fastest-growing segment.
• Integration of AI and machine learning into ART procedures is enhancing treatment precision and success rates.
• North America leads the market, while Asia Pacific is expected to post the fastest growth over the forecast period.
• Vitrolife, CooperSurgical, and Merck KGaA are among the leading providers shaping the competitive landscape.

Full report access: https://www.strategicrevenueinsights.com/industry/assisted-reproductive-technology-art-market

Delayed Parenthood and Genetic Screening Are Redrawing the Patient Base

The most consistent driver behind ART demand is the rising rate of infertility tied to delayed childbearing in developed and urbanizing economies, which has steadily expanded the pool of patients seeking treatment later in reproductive life. That shift has been compounded by broader social acceptance of diverse family formation, which has widened the patient base beyond traditional demographics. Government initiatives and supportive policies, including subsidies and expanded insurance and employer benefit coverage, are making treatment more affordable and encouraging more individuals to pursue ART services rather than delay or forgo care.

Clinical improvements are reinforcing this demand growth. Advances in vitrification and embryo selection are raising success rates per cycle, and the integration of AI and machine learning into diagnosis and treatment planning is improving precision, giving clinics a stronger case for recommending ART earlier rather than as a last resort. Preimplantation Genetic Testing is benefiting directly from this trend, as improved genetic screening technologies make it easier to identify viable embryos and reduce the number of cycles a patient needs.

A third factor is the growing normalization of elective fertility preservation. More individuals are choosing egg and embryo freezing to delay parenthood for personal or professional reasons, a trend supported by advances in cryopreservation techniques that better protect the viability of frozen specimens. This is lifting demand for cryopreservation systems and cryobank storage alongside core treatment procedures.

Market Segmentation

By procedure type, In Vitro Fertilization holds the largest share due to its high success rates and improved accessibility, while Preimplantation Genetic Testing is the fastest-growing procedure as genetic screening technology advances; Intracytoplasmic Sperm Injection, Intrauterine Insemination, Frozen Embryo Transfer, and Egg & Embryo Freezing round out the segment.

By product, ART Instruments & Equipment and Culture Media & Consumables are core to every treatment cycle, while Cryopreservation Systems are gaining prominence as egg and embryo freezing becomes more common; Accessory Products such as catheters and needles remain a steady, cycle-linked category.

By cycle type, Fresh Donor Cycles and Fresh Non-Donor Cycles remain the most common due to higher success rates, while Frozen Donor Cycles and Frozen Non-Donor Cycles are gaining share for their cost-effectiveness and reduced complication risk, particularly in regions with stringent egg-donation regulations.

By end use, Fertility Clinics are the primary providers of ART services, followed by Hospitals & Surgical Centers offering comprehensive fertility care. Cryobanks are growing alongside rising demand for egg and embryo freezing, and Research Institutes continue to contribute through studies and trials aimed at developing new fertility treatments.

Regional Outlook

North America is the largest regional market, supported by advanced healthcare infrastructure and high adoption rates, while Asia Pacific is projected to be the fastest-growing region, driven by increasing infertility rates and rising awareness of fertility treatments. Europe, Latin America, and the Middle East & Africa round out the report's regional coverage, each contributing to overall market expansion as awareness and access to ART services continue to grow.

Competitive Landscape

Vitrolife is known for its culture media, cryopreservation systems, and ART instruments, with a strong focus on R&D and strategic collaborations that support fertility clinics and hospitals. CooperSurgical offers a comprehensive product portfolio spanning ART instruments, culture media, and cryopreservation systems, and has built a strong global presence across fertility clinics and hospitals. Merck KGaA is recognized for its fertility drugs, culture media, and ART instruments, backed by strong R&D capabilities and strategic partnerships that support its position across the fertility care value chain.

Market Restraints

Market growth is constrained by high treatment costs, which can put ART procedures out of reach for many patients. Access is also uneven, with ART services often concentrated in urban areas, making it difficult for individuals in rural or remote regions to reach fertility treatment.

Related Reports

https://www.strategicrevenueinsights.com/industry/ecg-resting-system-market

https://www.strategicrevenueinsights.com/industry/enteral-feeding-devices-market

https://www.strategicrevenueinsights.com/industry/food-allergy-treatment-market

https://www.strategicrevenueinsights.com/industry/fragmentable-nasal-and-ear-dressings-market

https://www.strategicrevenueinsights.com/industry/green-lipped-mussel-powder-market

Frequently Asked Questions

How big is the assisted reproductive technology market?

The market was valued at USD 32.0 billion in 2025 and is projected to reach USD 69.5 billion by 2034, growing at a CAGR of 9.00%.

What is driving growth in the ART market?

Growth is driven by increasing infertility rates, advancements in ART procedures, and rising awareness about fertility treatments.

Which region leads the ART market?

North America is the largest regional market, while Asia Pacific is expected to grow the fastest during the forecast period.

Who are the leading companies in the ART market?

Leading companies named in the report include Vitrolife, CooperSurgical, and Merck KGaA.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases